Autopsy report · NCT04475991
Safety and Efficacy of Maraviroc and/or Favipiravir With Standard Therapy in Severe COVID-19 Adults
Cause of deathSlow enrollment
“No more patients complying the selection criteria were available for recruitment”
Life of this trial
- Registered 1 year before it started.
- Ran for about 8 months before it stopped.
- 19 participants enrolled.
- No results are posted on the registry.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Hospital General de México Dr. Eduardo Liceaga
- Sponsor type
- Government (non-US federal)
- Conditions
- COVID-19
- Interventions
- Maraviroc + Currently used therapy; Curently used therapy for COVID-19 non-critical patients; Favipiravir + Currently used therapy; Maraviroc+Favipiravir+CT
- Participants
- 19
- Sites
- 1
- Countries
- Mexico
Trials that died the same way
- Vitamin D Levels In Patients Who Has Normal to Grade 2 Knee Arthroscopy Changes
“Lack of patients with recruitment criteria” - Esophageal Balloon Guided Weaning of the Morbidly Obese Patient
“Minimal recruitment. very few patients available with eligibility criteria” - Specific Enteral Nutrition in Malnourished, Dialysis Patients With Chronic Kidney Disease. Efficacy, Safety, Quality of Life
“No Patient recruitment” - Near Infrared Spectroscopy in Patients Undergoing Robotic Assisted Laparoscopic Surgery in the Trendelenburg Position
“No sufficient patient recruitment” - Phosphodiesterase (PDE) Inhibitors Effect on Cognitive Deficits Associated to Schizophrenia
“Patient recruitment insufficient”
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.